Treatment characteristics and bleeding before ITI
| . | Before ITI, overall . | No prophylaxis . | Prophylaxis with rFVIIa . | Prophylaxis with aPCC . |
|---|---|---|---|---|
| Number or median (P25-P75) | ||||
| Patients | 115 | 98 | 16 | 1 |
| Treatment courses | 125 | 108 | 16 | 1 |
| Follow-up, y | 0.71 (0.39-1.38) | 0.77 (0.40-1.36) | 0.48 (0.28-1.91) | 0.61 |
| Age, y | 1.23 (0.79-1.62) | 1.19 (0.74-1.52) | 1.63 (1.04-3.10) | 1.96 |
| Maximum inhibitor titer (BU) | 6 (3-27) | 6 (3-27) | 3 (1-112) | Unknown |
| BPA prophylaxis | ||||
| Infusions per wk | NA | 2.8 (2-3.4) | 2 | |
| Dose/kg per wk (μg for rFVIIa and IU for aPCC) | NA | 360 (290-660) | 84 | |
| Bleeding | ||||
| ABR (mean, 95% CI) | 6.06 (4.98-7.39) | 5.94 (4.80-7.35) | 6.69 (3.86-11.58) | 9.78 |
| AJBR (mean, 95% CI) | 2.62 (2.11-3.24) | 2.38 (1.88-3.01) | 4.09 (2.33-7.18) | 3.26 |
| . | Before ITI, overall . | No prophylaxis . | Prophylaxis with rFVIIa . | Prophylaxis with aPCC . |
|---|---|---|---|---|
| Number or median (P25-P75) | ||||
| Patients | 115 | 98 | 16 | 1 |
| Treatment courses | 125 | 108 | 16 | 1 |
| Follow-up, y | 0.71 (0.39-1.38) | 0.77 (0.40-1.36) | 0.48 (0.28-1.91) | 0.61 |
| Age, y | 1.23 (0.79-1.62) | 1.19 (0.74-1.52) | 1.63 (1.04-3.10) | 1.96 |
| Maximum inhibitor titer (BU) | 6 (3-27) | 6 (3-27) | 3 (1-112) | Unknown |
| BPA prophylaxis | ||||
| Infusions per wk | NA | 2.8 (2-3.4) | 2 | |
| Dose/kg per wk (μg for rFVIIa and IU for aPCC) | NA | 360 (290-660) | 84 | |
| Bleeding | ||||
| ABR (mean, 95% CI) | 6.06 (4.98-7.39) | 5.94 (4.80-7.35) | 6.69 (3.86-11.58) | 9.78 |
| AJBR (mean, 95% CI) | 2.62 (2.11-3.24) | 2.38 (1.88-3.01) | 4.09 (2.33-7.18) | 3.26 |
NA, not applicable; P25, IQR 25th percentile; P75, IQR 75th percentile.